Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York

Regulatory News:

Medincell (Paris:MEDCL):

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell's portfolio and R&D pipeline at the Jefferies Global Healthcare Conference on June 6 at 1:00pm ET (19h00 CEST) at the Marriott Marquis Hotel in New York City

Investors can access the presentation remotely, either live or on replay, following this link: https://wsw.com/webcast/jeff302/mebgr/1977936

1X1 meetings with the management team may be arranged by directly contacting MedinCell: [e-mail]

“Our American strategy initiated last summer is already paying off. Top US investors, who have fully understood Medincell's short- and long-term potential, are on board. They are essential partners of our accelerating growth.”, said Christophe Douat, CEO of Medincell.

"With the successful launch of Teva-partnered UZEDY and positive phase 3 results for mdc-TJK, a potentially first-mover LAI olanzapine product with no black-box warning for severe schizophrenia, our well-validated BEPO technology continues to attract strong alliances including the recently announced major partnership with AbbVie. With additional early- and late-stage pipeline programs, encouraging data on Ph3 mdc-CWM, and additional upcoming catalysts - we look forward to sharing our progress and plans with fundamental investors," said Grace Kim, Medincell Head of US Financial Strategy.

Medincell has recently reached the commercial stage with the market launch by Teva of UZEDY for the treatment of schizophrenia. UZEDY is the first innovative product based on Medincell’s long-acting injectable (LAI) BEPO technology approved by US FDA.

Teva has recently confirmed the annual revenue guidance for UZEDY, projecting approximately $80 million for 2024. This revenue estimate is in line with Medincell's anticipated earnings from UZEDY, as the company is set to receive royalties from sales and could earn up to $105 million in commercial milestones.

In parallel, Medincell is developing a portfolio of innovative treatments also using the BEPO technology. This notably includes the following candidate treatments:

2 candidates in clinical Phase 3:

• mdc-TJK (in partnership with Teva): potentially, the first long-acting injectable olanzapine with a favorable safety profile that could enable a large adoption for treatment of patients with more severe forms of schizophrenia. Positive efficacy results have recently been announced. (press release)

• mdc-CWM (in partnership with AIC): an innovative sustained-release formulation of a non-steroidal anti-inflammatory drug celecoxib aiming at facilitating patient recovery after total knee replacement and decreasing the need for potentially addictive opioids. The encouraging results of the first phase 3 presented recently have paved the way for the next stages of regulatory development. (press release)

2 candidates in preclinical stage: